INmune Bio, Inc. (INMB) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 6 Buy, 2 Hold, 1 Sell.
The consensus price target is $22.00, representing an upside of 1646% from the current price $1.26.
Analysts estimate Earnings Per Share (EPS) of $-2.26 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.08 vs est $-2.26 (beat +7.9%). Analyst accuracy: 91%.
INMB Stock — 12-Month Price Forecast
$22.00
▲ +1,646.03% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for INmune Bio, Inc., the price target is $22.00.
The average price target represents a +1,646.03% change from the last price of $1.26.
INMB Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to INmune Bio, Inc. in the past 3 months
EPS Estimates — INMB
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.08
vs Est –$2.26
▲ 8.6% off
2025
Actual $0.00
vs Est –$1.59
▲ 0.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS trend is improving.
Revenue Estimates — INMB
50%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 50.0% off
2025
Actual $0.000B
vs Est $0.000B
▼ 50.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
